Adverum Biotechnologies, Inc.
ADVMAdverum Biotechnologies, Inc. (formerly known as Avalanche Biotechnologies) is a publicly traded clinical stage gene therapy company located in Redwood City, California. It is targeting unmet medical needs for serious ocular and rare diseases, including wet age-related macular degeneration (wet AMD).
Drugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Next quarter
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
Aflibercept
Neovascular Age-Related Macular Degeneration (nAMD)
6E11 vg/eye of ADVM-022
Diabetic Macular Edema
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Aflibercept | Phase 3 | Neovascular Age-Related Macular Degeneration (nAMD) | - | |
6E11 vg/eye of ADVM-022 | Phase 2 | Diabetic Macular Edema | - | - |
Neovascular Age-Related Macular Degeneration (nAMD)
1 drug in this indication
Diabetic Macular Edema
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Adverum Biotechnologies, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Adverum Biotechnologies, Inc.'s (ADVM) pipeline across Phase 3, Phase 2. Its lead program is Aflibercept (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Adverum Biotechnologies, Inc.'s next FDA catalyst?→
Adverum Biotechnologies, Inc.'s (ADVM) next tracked catalyst is a Phase 3 expected December 22, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ADVM biotech catalysts?→
Add ADVM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Adverum Biotechnologies, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.